

DAFTAR PUSTAKA

1. Hoffbrand AV, Pettit JE, Vyas P. Color Atlas of Clinical Hematology. 4th ed. Meloni D, Pushaw E, DePaul K, Orniston J, editor. Philadelphia: Harcourt; 2010.
2. Lichtman MA, Kaushansky K, Prchal JT, Levi MM, Inda, Burns J, et al. Williams Manual of Hematology, Tenth Edition. New York; 2022.
3. Panch SR, Montemayor C. Hemolytic transfusion reactions. Rossi's Principles of Transfusion Medicine. 2022.
4. Daniels G, Poole J, De Silva M, Callaghan T, MacLennan S, Smith N. The clinical significance of blood group antibodies. Transfusion Medicine. 2002.
5. Bhuvani Di, Vachhani J. Red cell alloimmunization in repeatedly transfused patients. Asian J Transfus Sci. 2017;11(2):115–20.
6. Agrawal A, Mathur A, Dontula S, Jagannathan L. Red Blood Cell Alloimmunization in Multi-transfused Patients: A Bicentric Study in India. 2016.
7. Das S, Biswas R, Safi M, Zaman R. Alloimmunization to erythrocyte antigens in patients receiving multiple blood transfusions: Clinico-immunohematological and demographic risk factors and impact of extended red cell phenotyping. Global Journal of Transfusion Medicine. 2021;6(2):171.
8. Kato H, Nakayama T, Uruma M, Okuyama Y, Handa M, Tomiyama Y, et al. Repeated exposure rather than the total volume of transfused components may influence the incidence of allergic transfusion reactions. Transfusion (Paris). 2015;55(11):2576–81.
9. Muche Y, Gelaw Y, Atnaf A, Getaneh Z. Blood Transfusion Complications and Associated Factors Among Blood-Transfused Adult Patients at Debre Markos Comprehensive Specialized Hospital, Ethiopia: A Cross Sectional Study. J Blood Med. 2023;14:389–98.
10. Dhawan HK, Kumawat V, Marwaha N, Sharma RR, Sachdev S, Bansal D, et al. Alloimmunization and autoimmunization in transfusion dependent thalassemia major patients: Study on 319 patients. Asian J Transfus Sci. 2014;8(2):84–8.
11. Valle Neto OG do, Alves VM, Pereira G de A, Moraes-Souza H, Martins PRJ. Clinical and epidemiological profile of alloimmunized and autoimmunized multi-transfused patients against red blood cell antigens in a blood center of Minas Gerais. Hematol Transfus Cell Ther. 1 April 2018;40(2):107–11.
12. Obaid JMAS, Abo El-Nazar SY, Ghanem AM, El-Hadidi AS, Mersal BHM. Red blood cells alloimmunization and autoimmunization among transfusion-dependent beta-thalassemia patients in Alexandria province, Egypt. Transfusion and Apheresis Science. 2015;53(1):52–7.
13. Philip J, Biswas AK, Hiregoudar S, Kushwaha N. Red blood cell alloimmunization in multitransfused patients in a tertiary care center in Western India. Lab Med. 2014;45(4):324–30.
14. Abdalkream Jawish TA, Hessen HM, Alshafeea MA, Mohamedahmed KA, Ahmed EA, Modawe GA, et al. Red Cell Alloimmunization in Repeatedly

- Transfused Sudanese Patients with leukemia in Northern Sudan. *Asian Pacific Journal of Cancer Prevention*. 2023;24(1):21–4.
15. Handa A, Kukar N, Maharishi R, Syal N, Arora H. Analysis of red cell alloimmunization in multi transfused patients at a Tertiary care teaching hospital. *J Family Med Prim Care*. 2020;9(6):2907.
 16. Mangwana S, Kacker A, Simon N. Red cell alloimmunization in multi-transfused, oncology patients: Risks and management. *Global Journal of Transfusion Medicine*. 2019;4(1):74.
 17. El Fetouh RMA, Elmoniem GMA, Allam RM, Sobeih ME, Kamel MM, Radwan SM. Frequency and specificity of Red blood cell alloantibodies in multitransfused Egyptian patients with hematological and nonhematological malignancies. *Transfusion and Apheresis Science*. 2020
 18. Romphruk A V., Simtong P, Butryojantho C, Pimphumee R, Junta N, Srichai S, et al. The prevalence, alloimmunization risk factors, antigenic exposure, and evaluation of antigen-matched red blood cells for thalassemia transfusions: a 10-year experience at a tertiary care hospital. *Transfusion (Paris)*. 2019;59(1):177–84.
 19. Rahajeng EP, Samad R, Muhiddin R. Identification of Risk Factors Characteristics of Transfusion Reaction.
 20. Budhiaty T. Rasio Prevalensi Alloantibodi Pada Pasien Transfusi Berulang Dibanding Tidak Berulang. Doctoral Dissertation, Universitas Gadjah Mada. 2013.
 21. Sari TA, Rofinda ZD, Yusri E. Gambaran Hasil Coomb's Test pada Pasien Keganasan Hematologi di RSUP Dr. M. Djamil Padang. 2022;45(2):160–6.
 22. Ghasemi A, Abbasian S, Ghaffari K, Salmanpour Z. Prevalence of Alloantibodies and Autoantibodies in Transfusion Dependent Thalassemia Patients. Vol. 8, *Iranian Journal Of Blood And Cancer* 80 Ijbc. 2016.
 23. Kuriri FA, Ahmed A, Alanazi F, Alhumud F, Ageeli Hakami M, Atiatalla Babiker Ahmed O. Red Blood Cell Alloimmunization and Autoimmunization in Blood Transfusion-Dependent Sickle Cell Disease and β -Thalassemia Patients in Al-Ahsa Region, Saudi Arabia. *Anemia*. 2023.
 24. Nahendran P, Balkis Budin S, Zakiah N, Saat M, Yusop MF, Norita T, et al. Red cell alloimmunization in multitransfused hepatobiliary patients at hospital Selayang. 2023.
 25. Chornenky Y, Gama AP, Felicelli C, Khurram N, Booth AL, Leventhal JR, et al. Alloimmunization Against RBC Antigens Is Not Associated With Decreased Survival in Liver Transplant Recipients. *Am J Clin Pathol*. 2023;159(3):255–62.
 26. Mulder FVM, Evers D, de Haas M, Cruijnsen MJ, Bernelot Moens SJ, Barcellini W, et al. Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps. *Front Immunol*. 2023;14.
 27. Molina-Aguilar S, Gómez-Ruiz J, Vela-Ojeda L, Montiel-Cervantes E, Reyes-Maldonado R, Reyes-Maldonado E, Montiel-Cervantes L. Pathophysiology of Alloimmunization. 2016.

28. Harmening D. *Modern Blood Banking & Transfusion Practices* Seventh Edition. Philadelphia; 2019.
29. Cap AP, Beckett A, Benov A, Borgman M, Chen J, Corley JB, et al. Whole blood transfusion. *Mil Med.* 2018;183:44–51.
30. Carson JL, Grossman BJ, Kleinman S, Timmouth AT, Marques MB, Fung MK, et al. *Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB**. 2012.
31. Cywinski JB. Blood products transfusion. Dalam: *Basic Sciences in Anesthesia*. Springer International Publishing; 2017.
32. Khawar H, Kelley W, Stevens JB, Guzman N. Fresh Frozen Plasma (FFP). *StatPearls.* 2022.
33. Mukherjee B. *Step by Step Technical Manual of Blood Components Preparation* A unit of whole blood can save four lives. 2016.
34. *Cryoprecipitate: thresholds and targets.* 2015.
35. Jones AR, Miller JL, Jansen JO, Wang HE. Whole Blood for Resuscitation of Traumatic Hemorrhagic Shock in Adults. *Adv Emerg Nurs J.* 2021;43(4):344–54.
36. Carson JL, Stanworth SJ, Dennis JA, Triyella M, Roubinian N, Fergusson DA, et al. Transfusion thresholds for guiding red blood cell transfusion. Vol. 2021, *Cochrane Database of Systematic Reviews*. John Wiley and Sons Ltd; 2021.
37. Woods GM, Sidonio RF. Coagulation concentrates for inherited bleeding disorders. *Rossi's Principles of Transfusion Medicine.* 2022;424–42.
38. Henricks LM, Huisman EJ, Lopriore E, Luken JS, de Haas M, Ootjers CS, et al. Acute haemolytic transfusion reaction after transfusion of fresh frozen plasma in a neonate—Preventable by using solvent/detergent-treated pooled plasma? *Transfusion Medicine.* 2023;33(2):174–8.
39. Garraud O, Hamzeh-Cognasse H, Chalayer E, Duchez AC, Tardy B, Oriol P, et al. Platelet transfusion in adults: An update. *Transfusion Clinique et Biologique.* Februari 2023;30(1):147–65.
40. Hinton J V., Xing Z, Fletcher CM, Perry LA, Karamesinis A, Shi J, et al. Association of Perioperative Cryoprecipitate Transfusion and Mortality After Cardiac Surgery. *Ann Thorac Surg.* 2023;116(2):401–11.
41. Bakta IM. *Hematologi Klinik Ringkas*. Jakarta: EGC; 2007.
42. Raval JS, Griggs JR, Fleg A. Blood Product Transfusion in Adults: Indications, Adverse Reactions, and Modifications. *Am Fam Physician.* 2020;102(1):30–8.
43. Sharma S, Sharma P, Tyler LN. *Transfusion of Blood and Blood Products: Indications and Complications.* Vol. 83. 2011.
44. De Oliveira Cruz R, Mota MA, Mendes Conti F, Antônio D' R, Pereira A, Kutner JM, et al. Prevalence of erythrocyte alloimmunization in polytransfused patients *Incidência de aloimunização eritrocitária em pacientes politransfundidos.* 2011;9(2):173–81.
45. Binder AF, Loos K, Xu ; Alexander, Peedin AR, Gergis U, Karp JK, et al. Optimizing Utilization of Blood Products in the Hematologic Malignancy Clinic: Less Is More. *JCO Oncol Pract.* 2022;18:1016–22.
46. Ferreira Costa F, Conran N. *Sickle Cell Anemia.* São Paulo; 2016.

47. Asare M, Hendrickson JE, Tormey CA. Determination of Red Blood Cell Alloimmunization Rates in Transfused Patients with Hematologic and Oncologic Malignancies. *Blood*. 2016;128(22):1463–1463.
48. Anita S, Am R, Arif M. Gambaran Direct Antiglobulin Test Pada Inkompatibilitas Description Of Direct Antiglobulin Test In Incompatibility.
49. Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Vol. 8, *Frontiers in Medicine*. Frontiers Media S.A.; 2021.
50. Hunnicutt J, Mahajan A, Gajjala R, Kharawala S, Richards A. #4424 frequency of red blood cell transfusion use in patients with anemia of chronic kidney disease (CKD) in europe: a systematic literature review. *Nephrology Dialysis Transplantation*. 2023.
51. Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent [Internet]. 2000.
52. Hafy Z, Liana P, Sriwijaya Jalan Raya Palembang-Prabumulih Km U, Ilir O, Selatan S, Imunologi dan Sains Transfusi B, et al. Comparison of the Proportion of Iregular Antibodies in Multitransfusion and Non Multitransfusion Patients at UTD RSUP Dr. Mohammad Hoesin Palembang. 2021.
53. El-Beshlawy A, Salama AA, El-Masry MR, El Husseiny NM, Abdelhameed AM. A study of red blood cell alloimmunization and autoimmunization among 200 multitransfused Egyptian β thalassemia patients. *Sci Rep*. 2020;10(1).
54. Molina-Aguilar R, Gómez-Ruiz S, Vela-Ojeda J, Montiel-Cervantes LA, Reyes-Maldonado E. Pathophysiology of Alloimmunization. *Transfusion Medicine and Hemotherapy*. 2020;47(2):152–9.
55. Parker V, Tormey CA. The Direct Antiglobulin Test: Indications, Interpretation, and Pitfalls. *Arch Pathol Lab Med*. 2017;141(2):305–10.
56. Zantek ND, Koepsell SA, Tharp DR, Cohn CS. The direct antiglobulin test: A critical step in the evaluation of hemolysis. *Am J Hematol*. 2012;87(7):707–9.
57. Zarandona JM, Yazer MH. The role of the Coombs test in evaluating hemolysis in adults. *CMAJ Canadian Medical Association Journal*. 2006;174(3):305–7.
58. Lin JS. Clinical applications of direct antiglobulin test. *Blood, Heart and Circulation*. 2018;2(4).
59. Ortona E, Pierdominici M, Maseli A, Veroni C, Aloisi F, Shoenfeld Y. Sex-based differences in autoimmune diseases. *Ann Ist Super Sanita*. 2016;52(2):205–12.
60. Noopetch P, Benchamanon R, Kongsuwan S, Chai-adisaksopha C. 252. Clinical Outcomes and Risk Factor of Severe Disease in Young Adult Patients Compared with Middle-Aged Patients Who Infected with COVID-19: A Large Cohort Study in Tertiary Hospital. *Open Forum Infect Dis*. 2022.

61. Mendes IC, de Assis PCGF, de Almeida RS, de Sousa LRR, Carneiro LC, Jesuino RSA. Clinical and laboratory profile of patients with positive direct antiglobulin test attended at a university hospital in Goias, Brazil. *Hematol Transfus Cell Ther.* 2024.
62. Schnieders E, Leon J, Chapman JM, Knudson CM. Patient ABO blood type is a major predictor of a positive following a transfusion reaction. *Transfusion (Paris).* 2022;62(9):1715–9.
63. Carson JL, Stanworth SJ, Dennis JA, Trivella M, Roubinian N, Fergusson DA, et al. Transfusion thresholds for guiding red blood cell transfusion. *Cochrane Database of Systematic Reviews.* 2021.
64. Schmitz L, Pirotte M, Lebeau A, Ernst M, Fillet M, Devey A, et al. Alterations of erythropoiesis in Covid-19 patients: prevalence of positive Coombs tests and iron metabolism. *Ther Adv Hematol.* 2023;14.
65. Triwianti Y, Cahyati WH, Rahayu R, Unnes K, Kelud J. Factors Affecting Hemoglobin Levels in Prospective Female Donors in Semarang Blood Centre. *Public Health Perspectives Journal.* 7(1):2022–71.
66. Matsuura H, Fujii S, Matsui Y, Sugiura Y, Akiyama H, Miura Y. An association between a positive direct antiglobulin test and HLA-DR12 in COVID-19. *Ann Hematol.* 2022;101(9):1959–69.
67. Abbas SA, Zeeshan R, Sultan S, Irfan SM. Direct coombs test positivity in B-chronic lymphoid leukemia: A marker of advanced clinical disease. *Asian Pacific Journal of Cancer Prevention.* 2015;16(14):6007–10.
68. Okutsu M, Ohto H, Yasuda H, Kawabata K, Ono S, Saito S, et al. Increased detection of clinically significant antibodies and decreased incidence of delayed haemolytic transfusion reaction with the indirect antiglobulin test potentiated by polyethylene glycol compared to albumin: A Japanese study. *Blood Transfusion.* 2011;9(3):311–9.
69. Hafez W, Ziade MA, Arya A, Saleh H, Abdelrahman A. The significance of antiglobulin (Coombs) test reactivity in patients with COVID-19. *Immunobiology.* 2022;227(4).
70. Isa HM, AlBuainain NY, Bunajem FY, Masood AS, Bucheery YA. Neonatal and Maternal Risk Factors for Indirect Hyperbilirubinemia: A Cross-Sectional Study from Bahrain. *Int J Pediatr.* 9 September 2022:1–8.
71. Elghetany M, Banki K. *Henry's Clinical Diagnosis and Management by Laboratory Methods.* 24th ed. Philadelphia: Elsevier; 2022.
72. Ozolek JA, Watchko JF, Mimouni F. Prevalence and lack of clinical significance of blood group incompatibility in mothers with blood type A or B. *J Pediatr.* 1994;125(1):87–91.
73. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. *Transfusion (Paris).* 2002;42(1):37–43.
74. Tiwari N, Mishra J, Sharma A, Kisanji Gadpayle A, Gupta N, Hospital S, et al. Article in *Community practitioner: the journal of the Community Practitioners' & Health Visitors' Association.* 2023.
75. Thedsawad A, Taka O, Wanachiwanawin W. Prevalence and clinical significances of red cell alloimmunization and red cell bound immunoglobulin G in polytransfused patients with thalassemias. *Hematology.* 2019;24(1):208–14.

76. Araújo CSR, Mattiello JM, Brittes LL, Meinhart M, Bortolotti P, Fior T, et al. Association Of Positive Direct Antiglobulin Test With Nonreactive Eluate And Drug-Induced Immune Hemolytic Anemia. *Hematol Transfus Cell Ther.* November 2020;42:382.

